Carl Koschmann, MD, PhD is a pediatric neuro-oncologist and the Clinical Scientific Director of the University of Michigan Chad Carr Pediatric Brain Tumor Center, and cares for children and young adults with brain tumors. He specializes in the research and treatment of high-risk brain tumors, including high-grade glioma, diffuse midline glioma (DMG), and diffuse intrinsic pontine glioma (DIPG). His NIH-funded laboratory explores mechanisms by which mutations in these tumors drive their formation and impact treatment response.
Dr. Koschmann also serves as the Co-Scientific Chair of the Children’s Brain Tumor Network, which is the largest pediatric brain tumor data and sample repository. He is the PI/Co-PI for multiple early phase studies in pHGG/DMG for which his lab performs analysis of correlate tumor and spinal fluid samples.
“The DIPG/DMG National Brain Tumor Board is a game changer for families and referring physicians of children with DIPG or DMG. This will allow families to consolidate their time and effort and have a panel of experts review their child’s case and provide advice in real time. This will be used primarily for families at major “decision forks” — at diagnosis, or post-radiation or at recurrence. We are very excited to be a part of this program which is truly unique.”